MedTrace Logo

Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection

NCT06314113 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-03-15

No results posted yet for this study

Summary

The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.

Conditions

  • Low-Grade Intraepithelial Neoplasia of Cervix

Interventions

DIETARY_SUPPLEMENT

Epigallocatechin Gallate

Oral treatment with Epigallocatechin Gallate 200 mg per day

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Antonio Simone Laganà, M.D., Ph.D. · University of Palermo

  • Giuseppe Mascellino, M.D. · University of Palermo

  • Pietro Serra, M.D. · University of Palermo

  • Andrea Etrusco, M.D. · University of Palermo

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-03-01
Completion
2025-09-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314113 on ClinicalTrials.gov